Aclaris Therapeutics: HC Wainwright Raises PT to $16 from $15.
ByAinvest
Monday, Oct 20, 2025 7:48 am ET1min read
ACRS--
The upgrade comes amidst a series of positive developments for Aclaris Therapeutics. The company recently reported earnings results for the second quarter and six months ended June 30, 2025, which included a beat on revenue estimates. Additionally, Aclaris Therapeutics has been making significant strides in its clinical trials, particularly with its investigational drug ATI-2138, which has achieved primary and key secondary endpoints in a Phase 2a trial.
The analyst community has been largely optimistic about Aclaris Therapeutics, with several firms maintaining a Buy rating and setting high price targets. For instance, Piper Sandler has a price target of $13, while Cantor Fitzgerald has upgraded the stock to Overweight with a price target of $20.
Aclaris Therapeutics' robust pipeline and strategic focus on immuno-inflammatory diseases position it as a promising player in the biotech sector. The company's KINect drug discovery platform and preclinical development capabilities are key assets that could drive future growth.
The upgrade by HC Wainwright underscores the growing interest and confidence in Aclaris Therapeutics' potential. Investors should closely monitor the company's progress in its ongoing clinical trials and regulatory submissions to gauge the stock's future performance.
Aclaris Therapeutics: HC Wainwright Raises PT to $16 from $15.
Aclaris Therapeutics, Inc. (ACRS) has seen a positive shift in analyst sentiment following an upgrade by HC Wainwright. The investment research firm has increased its price target for Aclaris Therapeutics from $15 to $16, reflecting a bullish outlook on the biopharmaceutical company's prospects.The upgrade comes amidst a series of positive developments for Aclaris Therapeutics. The company recently reported earnings results for the second quarter and six months ended June 30, 2025, which included a beat on revenue estimates. Additionally, Aclaris Therapeutics has been making significant strides in its clinical trials, particularly with its investigational drug ATI-2138, which has achieved primary and key secondary endpoints in a Phase 2a trial.
The analyst community has been largely optimistic about Aclaris Therapeutics, with several firms maintaining a Buy rating and setting high price targets. For instance, Piper Sandler has a price target of $13, while Cantor Fitzgerald has upgraded the stock to Overweight with a price target of $20.
Aclaris Therapeutics' robust pipeline and strategic focus on immuno-inflammatory diseases position it as a promising player in the biotech sector. The company's KINect drug discovery platform and preclinical development capabilities are key assets that could drive future growth.
The upgrade by HC Wainwright underscores the growing interest and confidence in Aclaris Therapeutics' potential. Investors should closely monitor the company's progress in its ongoing clinical trials and regulatory submissions to gauge the stock's future performance.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
Comments
No comments yet